Could a new pill help regulate blood sugar? early trial puts PSTC100 to the test

NCT ID NCT07752472

Not yet recruiting Knowledge-focused Sponsor: Prospect Therapeutics (Nanjing) Limited Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This first-in-human trial evaluates the safety and tolerability of an investigational drug called PSTC100, given as tablets to healthy adults aged 18 to 55. Participants receive either the drug or a placebo in increasing doses, and researchers track how the body absorbs, processes, and eliminates the drug. The study also looks at early signals of how PSTC100 might affect glucose metabolism, which could hint at future uses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSTC100 tablets
What this could lead to: If successful, this early trial could pave the way for larger studies exploring PSTC100's effects on glucose metabolism and other health markers.
What could go wrong: This is a small, early-stage study focused on safety, not effectiveness. The drug may not prove safe or may not show meaningful effects in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT SUBJECTS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Nucleus Network Sydney Pty Ltd

Saint Leonards, New South Wales, 2065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.